Predicting late recurrence of breast cancer - European Medical Journal

Predicting late recurrence of breast cancer


At the 14th St. Gallen International Breast Cancer Conference 2015, Eleftherios P. Mamounas, MD, of University of Florida Health Cancer Center-Orlando Health, discusses the use of multigene assays, which analyse the activity of groups of genes in breast cancer cells, for predicting late recurrence in patients with early stage, oestrogen receptor-positive breast cancer.

An example of a multigene assay is the Oncotype DX® Breast Cancer Assay, which was developed to stratify the risk of recurrence in patients with breast cancer after initial tamoxifen therapy. Information gained from the Oncotype DX assay may be used to help identify patients who are likely, or unlikely, to benefit from adjuvant chemotherapy.

This content is supported by Genomic Health, Inc.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now